X
Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthritis
https://pharmaphorum.com/news/novartis-cosentyx-cant-exceed-humira-in-psoriatic-arthritis/
Cosentyx
Amid tough competition, Novartis makes case for rheumatology drug Cosentyx
Swiss pharma hopes to bounce back from Q1 sales disappointment
Imbruvica, Opdivo and Praluent gain approvals for Scotland’s NHS
Sanofi steals a march on rivals Amgen